Clinical Trial Update: An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma [Phase 4]

View source ↗

Summary

Phase 4 safety trial of nivolumab in advanced or metastatic renal cell carcinoma completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Renal Cell Carcinoma | Phase 4 | Status: COMPLETED | Results posted: 2019-08-28